[Susceptibility testing and molecular epidemiology of clinical strains of Bordetella pertussis isolated in Japan from 2001 to 2002].
We determined antimicrobial susceptibilities and analyzed molecular epidemiology of 26 strains of Bordetella pertussis clinically isolated and then performed pulsed-field gel electrophoresis (PFGE) in Japan (Japanese Pertussis Surveillance Group Participants), from 2001 to 2002. The MICs of erythromycin, clindamycin, tetracyclines, fluoroquinorones, trimethoprim-sulfamethoxazole and rifampicin of all isolates against these showed 1 microgram/ml or less. Sparfloxacin is the most potent agent, of which the MICs showed 0.008-0.016 microgram/ml. Results of DNA fingerprinting by pulsed-field gel electrophoresis (PFGE) differentiated three types (Type I; 11 strains (42%), type II; 14 strains (54%) and type III; 1 strains (4%)). However, no relation between regions and identical PFGE patterns was found in this study. Further, surveillance of the antimicrobial susceptibilities and molecular epidemiology of B. pertussis will be required.
Ohtsuka
Masayuki
M
Kotobiken Medical Laboratories Inc.
Kikuchi
Ken
K
Okada
Kenji
K
Higashide
Masato
M
Shundo
Kazuya
K
Sunakawa
Keisuke
K
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001886:Bordetella pertussis / Q000187:drug effects* / Q000235:genetics*; D002675:Child, Preschool; D004269:DNA, Bacterial / Q000032:analysis / Q000145:classification; D024881:Drug Resistance, Bacterial; D016521:Electrophoresis, Gel, Pulsed-Field; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D024841:Fluoroquinolones / Q000494:pharmacology; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D017720:Molecular Epidemiology; D012293:Rifampin / Q000494:pharmacology; D013754:Tetracyclines / Q000494:pharmacology; D014917:Whooping Cough / Q000453:epidemiology*
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D013754:Tetracyclines; D004917:Erythromycin; C061363:sparfloxacin; D012293:Rifampin